相关实验视频

Updated: Jul 11, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

365

新辅助剂PD-1/PD-L1与CTLA-4抑制剂结合用于固体恶性瘤:系统性审查和元分析

Shuang Huang1, Gang Zheng2, Kai Yang3

  • 1Department of Stomatology, Shapingba Hospital affiliated to Chongqing University, No.44, Xiaolongkan New Street, Chongqing, Shapingba District, 400030, China.

World journal of surgical oncology
|November 5, 2023
PubMed
概括

将编程细胞死亡蛋白1 (PD-1) /编程死亡配体1 (PD-L1) 抑制剂与细胞毒性T淋巴细胞相关蛋白4 (CTLA-4) 抑制剂作为固体瘤的新辅助疗法相结合,不会提高疗效. 这种组合可能会增加严重不良事件的风险.

关键词:
在 CTLA-4 中.免疫检查点抑制剂 免疫检查点抑制剂进行元分析分析.新辅助疗法是一种新辅助疗法.在PD-1中使用PD-1.在PD-L1中.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K